Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 465.0
(1.97%)
SEK 465.0
(1.97%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 250.56 Million SEK | -17.29% |
| 2022 | 302.94 Million SEK | 17.81% |
| 2021 | 257.14 Million SEK | 81.28% |
| 2020 | 141.84 Million SEK | 149.0% |
| 2019 | 56.96 Million SEK | 23.48% |
| 2018 | 46.13 Million SEK | 34.87% |
| 2017 | 34.2 Million SEK | 4.03% |
| 2016 | 32.88 Million SEK | 70.33% |
| 2015 | 19.3 Million SEK | -24.34% |
| 2014 | 25.51 Million SEK | -17.5% |
| 2013 | 30.93 Million SEK | 20.1% |
| 2012 | 25.75 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 248.18 Million SEK | -0.94% |
| 2024 Q3 | 195.01 Million SEK | -21.42% |
| 2024 Q1 | 250.54 Million SEK | -0.01% |
| 2023 FY | 250.56 Million SEK | -17.29% |
| 2023 Q3 | 308.99 Million SEK | 8.38% |
| 2023 Q2 | 285.09 Million SEK | -2.69% |
| 2023 Q4 | 250.56 Million SEK | -18.91% |
| 2023 Q1 | 292.98 Million SEK | -3.29% |
| 2022 Q4 | 302.94 Million SEK | 16.58% |
| 2022 Q1 | 224.98 Million SEK | -12.51% |
| 2022 FY | 302.94 Million SEK | 17.81% |
| 2022 Q3 | 259.86 Million SEK | 8.73% |
| 2022 Q2 | 239 Million SEK | 6.23% |
| 2021 FY | 257.14 Million SEK | 81.28% |
| 2021 Q1 | 146.21 Million SEK | 3.08% |
| 2021 Q2 | 138.82 Million SEK | -5.06% |
| 2021 Q3 | 131.83 Million SEK | -5.03% |
| 2021 Q4 | 257.14 Million SEK | 95.05% |
| 2020 Q2 | 50.75 Million SEK | -8.39% |
| 2020 Q3 | 77.2 Million SEK | 52.11% |
| 2020 Q4 | 141.84 Million SEK | 83.73% |
| 2020 Q1 | 55.4 Million SEK | -2.74% |
| 2020 FY | 141.84 Million SEK | 149.0% |
| 2019 Q4 | 56.96 Million SEK | -23.64% |
| 2019 FY | 56.96 Million SEK | 23.48% |
| 2019 Q1 | 58.61 Million SEK | 27.05% |
| 2019 Q2 | 70.9 Million SEK | 20.98% |
| 2019 Q3 | 74.59 Million SEK | 5.2% |
| 2018 Q3 | 44.11 Million SEK | 6.78% |
| 2018 FY | 46.13 Million SEK | 34.87% |
| 2018 Q1 | 33.66 Million SEK | -1.6% |
| 2018 Q2 | 41.31 Million SEK | 22.74% |
| 2018 Q4 | 46.13 Million SEK | 4.58% |
| 2017 FY | 34.2 Million SEK | 4.03% |
| 2017 Q1 | 25.24 Million SEK | -23.24% |
| 2017 Q2 | 28.76 Million SEK | 13.96% |
| 2017 Q3 | 30.18 Million SEK | 4.92% |
| 2017 Q4 | 34.2 Million SEK | 13.33% |
| 2016 Q1 | 20.94 Million SEK | 8.5% |
| 2016 Q4 | 32.88 Million SEK | 7.5% |
| 2016 Q2 | 23.96 Million SEK | 14.38% |
| 2016 Q3 | 30.58 Million SEK | 27.67% |
| 2016 FY | 32.88 Million SEK | 70.33% |
| 2015 Q1 | 22.52 Million SEK | -11.71% |
| 2015 Q2 | 25.28 Million SEK | 12.22% |
| 2015 Q4 | 19.3 Million SEK | -12.2% |
| 2015 FY | 19.3 Million SEK | -24.34% |
| 2015 Q3 | 21.98 Million SEK | -13.03% |
| 2014 Q1 | 33.08 Million SEK | 6.95% |
| 2014 Q2 | 39.44 Million SEK | 19.23% |
| 2014 Q3 | 21.99 Million SEK | -44.24% |
| 2014 Q4 | 25.51 Million SEK | 16.03% |
| 2014 FY | 25.51 Million SEK | -17.5% |
| 2013 Q4 | 30.93 Million SEK | 31.51% |
| 2013 Q2 | 19.56 Million SEK | 10.52% |
| 2013 FY | 30.93 Million SEK | 20.1% |
| 2013 Q1 | 17.7 Million SEK | -31.25% |
| 2013 Q3 | 23.52 Million SEK | 20.2% |
| 2012 Q4 | 25.75 Million SEK | 0.0% |
| 2012 FY | 25.75 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -2178.287% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 90.63% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 90.63% |
| Arcoma AB | 33.3 Million SEK | -652.337% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 24.002% |
| BICO Group AB (publ) | 3.26 Billion SEK | 92.325% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 10.48% |
| CellaVision AB (publ) | 212.32 Million SEK | -18.012% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -1664.922% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -3547.812% |
| C-Rad AB (publ) | 122.4 Million SEK | -104.711% |
| Duearity AB (publ) | 17.53 Million SEK | -1329.355% |
| Dignitana AB (publ) | 37.56 Million SEK | -566.984% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -1165.485% |
| Getinge AB (publ) | 24.69 Billion SEK | 98.985% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -1116.322% |
| Iconovo AB (publ) | 14.55 Million SEK | -1621.642% |
| Integrum AB (publ) | 22.07 Million SEK | -1035.177% |
| Luxbright AB (publ) | 7 Million SEK | -3479.453% |
| Mentice AB (publ) | 163.55 Million SEK | -53.201% |
| OssDsign AB (publ) | 105.25 Million SEK | -138.052% |
| Paxman AB (publ) | 44.5 Million SEK | -462.956% |
| Promimic AB (publ) | 16.15 Million SEK | -1450.916% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -303.04% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -1077.582% |
| ScandiDos AB (publ) | 37.18 Million SEK | -573.818% |
| Sectra AB (publ) | 1.64 Billion SEK | 84.734% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -468.667% |
| Senzime AB (publ) | 58.06 Million SEK | -331.527% |
| SpectraCure AB (publ) | 14.97 Million SEK | -1573.229% |
| Stille AB | 172.64 Million SEK | -45.138% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 93.169% |